Optimizing Janus kinase inhibitor therapy for ulcerative colitis: a real-world perspective

Area of Science:

• Gastroenterology and Hepatology
• Immunology
• Pharmacology

Background:

• Three Janus kinase (JAK) inhibitors, tofacitinib, filgotinib, and upadacitinib, are available for ulcerative colitis treatment.
• Real-world evidence indicates differing efficacy and safety profiles among these JAK inhibitors.
• Differences in JAK selectivity and dosing strategies contribute to observed variations in treatment outcomes.

Purpose of the Study:

• To review clinical trials and real-world data for tofacitinib, filgotinib, and upadacitinib in ulcerative colitis.
• To discuss the distinct efficacy and safety profiles of these JAK inhibitors.
• To explore strategies for optimizing the clinical application of JAK inhibitors in ulcerative colitis management.

Main Methods:

• Systematic review of published clinical trials.
• Analysis of emerging real-world evidence and observational studies.
• Synthesis of data on JAK inhibitor selectivity, dosing, efficacy, and safety.

Main Results:

• Accumulating data reveal differential efficacy and predictors of response for JAK inhibitors.
• Patient outcomes after switching between JAK inhibitors are being documented.
• Key safety concerns include herpes zoster infections and drug-induced acne, necessitating risk assessment.

Conclusions:

• Optimizing the use of JAK inhibitors in ulcerative colitis requires understanding their distinct profiles.
• Individualized risk assessment and patient education are crucial for managing safety concerns.
• Further research into predictors of response and long-term outcomes will refine treatment strategies.